Lifeboat Foundation

Mike Kelly is President & Chief Executive Officer of NervGen Pharma Corp. (https://nervgen.com/), a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.

NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Continue reading “Mike Kelly — President & CEO, NervGen Pharma — Innovative Treatments To Enable Nervous System Repair” »

This breakthrough could be used to make eco-friendly houses and structures in the near future.first appeared on The Cool Down.

Hackers made off with the info of 31 million users.

Quantum theory describes events that take place on extremely short time scales. In the past, such events were regarded as ‘momentary’ or ‘instantaneous’: An electron orbits the nucleus of an atom—in the next moment it is suddenly ripped out by a flash of light. Two particles collide—in the next moment they are suddenly ‘quantum entangled.’

A research team has made a breakthrough in significantly enhancing the commercial viability of spin wave harnessing technology. This innovation is being heralded as a next-generation technological solution to the persistent issue of heat generation in electronic devices. The research findings were published on September 26 in the online edition of Matter.

A difficult-to-describe nanoscale object called the magnetic skyrmion might one day yield new microelectronic devices that can do much more—for example, massive data storage—all while consuming much less power.

In an advance that could revolutionize biomarker detection, researchers at the Max Planck Institute for the Science of Light have developed a novel technique called femtosecond fieldoscopy. This method enables the precise measurement of minute liquid quantities, down to the micromolar level, with unmatched sensitivity in the near-infrared region.

“There’s way more piloting that I’ve seen, especially in large law firms. So, there’s been a lot of expense, especially the allocating of staff and paying out of pocket for licensing fees,” Friedmann said.

“Part is keeping up with the Joneses, part of it is marketing, and part of it is just getting over the adoption challenges,” he continued. “In eDiscovery, before the advent of genAI, you needed some training to know how to interact with discovery database. There were a lot of tools, but they all had the same issue: You had to be pretty technically adept to tackle the database yourself.”

Continue reading “GenAI surges in law firms: Will it spell the end of the billable hour?” »

A type of mathematical problem that was previously impossible to solve can now be successfully analysed with artificial intelligence.

By Chris Stokel-Walker